Eli Lilly’s October 2024 non-exclusive research agreement with Peptron granted only internal evaluation rights for SmartDepot, its ultrasonic spray-dried PLGA microsphere platform for one- to six-month peptide sustained release, without commercial manufacturing or licensing terms. Nearly two years later, no binding technology-transfer or commercial deal has been publicly disclosed, while Lilly separately partnered with Camurus in June 2026 for the competing FluidCrystal platform targeting long-acting incretins. With just weeks remaining until the October 7, 2026 resolution date, the absence of announced progress on feasibility data, technology transfer, or expanded terms sustains the strong market-implied odds against a formal license materializing in time.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% โอกาส
$11,264 ปริมาณ
$11,264 ปริมาณ
Oct 7, 2026
13% โอกาส
$11,264 ปริมาณ
$11,264 ปริมาณ
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 non-exclusive research agreement with Peptron granted only internal evaluation rights for SmartDepot, its ultrasonic spray-dried PLGA microsphere platform for one- to six-month peptide sustained release, without commercial manufacturing or licensing terms. Nearly two years later, no binding technology-transfer or commercial deal has been publicly disclosed, while Lilly separately partnered with Camurus in June 2026 for the competing FluidCrystal platform targeting long-acting incretins. With just weeks remaining until the October 7, 2026 resolution date, the absence of announced progress on feasibility data, technology transfer, or expanded terms sustains the strong market-implied odds against a formal license materializing in time.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: May 5, 2026, 8:02 PM ET
ปริมาณการซื้อขาย
$11,264วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 non-exclusive research agreement with Peptron granted only internal evaluation rights for SmartDepot, its ultrasonic spray-dried PLGA microsphere platform for one- to six-month peptide sustained release, without commercial manufacturing or licensing terms. Nearly two years later, no binding technology-transfer or commercial deal has been publicly disclosed, while Lilly separately partnered with Camurus in June 2026 for the competing FluidCrystal platform targeting long-acting incretins. With just weeks remaining until the October 7, 2026 resolution date, the absence of announced progress on feasibility data, technology transfer, or expanded terms sustains the strong market-implied odds against a formal license materializing in time.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$11,264วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s October 2024 non-exclusive research agreement with Peptron granted only internal evaluation rights for SmartDepot, its ultrasonic spray-dried PLGA microsphere platform for one- to six-month peptide sustained release, without commercial manufacturing or licensing terms. Nearly two years later, no binding technology-transfer or commercial deal has been publicly disclosed, while Lilly separately partnered with Camurus in June 2026 for the competing FluidCrystal platform targeting long-acting incretins. With just weeks remaining until the October 7, 2026 resolution date, the absence of announced progress on feasibility data, technology transfer, or expanded terms sustains the strong market-implied odds against a formal license materializing in time.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย